Nuvation Bio Inc. (NUVB) saw an 8.43% increase, reaching $8.10, after positive Phase 2 trial results for safusidenib in patients with grade-2 IDH1-mutant glioma. The data showed promising safety and efficacy, offering hope for a new neuro-oncology treatment. Trading activity surged as investors reacted, with volume exceeding average levels. The stock’s 52-week range is $4.20 – $9.45.

Read more at Nasdaq: Nuvation Bio Shares Rise 8.4% After Positive Phase 2 Results In Grade-2 IDH1 Glioma